The 2011 Leading Life Science Intermediates Companies R&D Expenditures and Major Programs

Complete report $1,850.  Individual company assessments $250.

The companies analyzed in this report include BASF, Cambrex, Clariant, DowPharma, DSM, Evonik, Lanxess, Lonza, Novasep, and Rhodia.

For each company, the report presents:

• Estimated R&D budget.

• Research facilities and staff.

• New technologies, products and applications in development.